Factory Mutual Insurance Co. lessened its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 2.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 551,277 shares of the biopharmaceutical company’s stock after selling 11,000 shares during the period. Factory Mutual Insurance Co.’s holdings in Bristol-Myers Squibb were worth $30,718,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. State Street Corp grew its stake in Bristol-Myers Squibb by 1.8% in the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after purchasing an additional 1,223,457 shares during the last quarter. Jennison Associates LLC grew its stake in Bristol-Myers Squibb by 0.8% in the first quarter. Jennison Associates LLC now owns 21,927,898 shares of the biopharmaceutical company’s stock valued at $1,192,439,000 after purchasing an additional 178,436 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Bristol-Myers Squibb by 18.7% in the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after purchasing an additional 2,451,390 shares during the last quarter. Legal & General Group Plc grew its stake in Bristol-Myers Squibb by 4.3% in the first quarter. Legal & General Group Plc now owns 8,213,428 shares of the biopharmaceutical company’s stock valued at $446,664,000 after purchasing an additional 335,795 shares during the last quarter. Finally, Swiss National Bank grew its stake in Bristol-Myers Squibb by 27.2% in the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock valued at $322,020,000 after purchasing an additional 1,267,900 shares during the last quarter. Institutional investors own 68.88% of the company’s stock.
Bristol-Myers Squibb Company (NYSE:BMY) traded up 0.57% during midday trading on Tuesday, hitting $63.06. The company had a trading volume of 1,981,873 shares. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $63.47. The firm has a 50-day moving average price of $58.77 and a 200-day moving average price of $55.98. The company has a market cap of $103.41 billion, a price-to-earnings ratio of 23.03 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.69 EPS. Equities analysts anticipate that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.49%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 56.73%.
Several research firms have issued reports on BMY. BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Vetr lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 target price on the stock. in a research note on Tuesday, August 22nd. Deutsche Bank AG set a $55.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, July 17th. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Wednesday, August 16th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $62.66.
TRADEMARK VIOLATION NOTICE: “Factory Mutual Insurance Co. Has $30.72 Million Holdings in Bristol-Myers Squibb Company (BMY)” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2017/09/19/factory-mutual-insurance-co-has-30-72-million-holdings-in-bristol-myers-squibb-company-bmy.html.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Theodore R. Samuels II bought 6,000 shares of the stock in a transaction on Wednesday, August 2nd. The stock was bought at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the purchase, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.